article thumbnail

Osivax publishes phase 2a results supporting dual flu vaccine approach

Pharma Times

The results, now published in Vaccines , show that the combination was well-tolerated with no serious adverse events, and generated strong immune responses. Robust NP-specific humoral and cell-mediated immune responses were observed in all participants given OVX836, whether alone or with Fluarix Tetra.

article thumbnail

The MEK effect on cancer — a slow and steady approach to drug resistance

PharmaVoice

Published July 8, 2025 By Kelly Bilodeau post share post print email license Stock via Getty Images Listen to the article 5 min This audio is auto-generated. You just want to slash it, rip it out or attack it like an enemy target,” said Benjamin Zeskind, co-founder, CEO and president of Immuneering Corporation.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

As its cancer vaccine moves through the clinic, Transgene sets sights on manufacturing

PharmaVoice

Published July 9, 2025 Amy Baxter Staff Reporter post share post print email license Stock via Getty Images Listen to the article 6 min This audio is auto-generated. The company’s myvac platform creates individualized immunotherapies that stimulate and “educate” a patient’s immune system to destroy cancer tumors.

Vaccines 179
article thumbnail

Implications of RFK Jr.’s CDC Vaccine Committee Overhaul for the Pharmaceutical Industry

PharmaTech

s CDC Vaccine Committee Overhaul for the Pharmaceutical Industry June 10, 2025 By Christopher Cole News Article The dismissal of all 17 members of the Advisory Committee on Immunization Practices has far-reaching impacts for the industry and beyond. On June 9, 2025, Secretary of Health and Human Services Robert F. June 9, 2025.

article thumbnail

APhA Foundation Drives Innovative Clinical Models at McKesson ideaShare 2025

Pharmacy Times

Innovative pharmacist-led care models—from tech-enabled Afib screenings and HPV immunizations to Medicare-supported diabetes prevention—demonstrate how pharmacies are redefining their role in team-based clinical care.

article thumbnail

Biocon Biologics gains market access coverage for Yesintek in the US

Express Pharma

Express Scripts has added Yesintek to the National Preferred Formulary (NPF) effective March 21, 2025. Cigna has added Yesintek to its commercial formulary beginning on March 21, 2025. CVS Health has added Yesintek beginning July 1, 2025. The available presentations are 45 mg/0.5 mL PFS, 90 mg/mL PFS, 45 mg/0.5

article thumbnail

Is biopharma dealmaking getting hot again?

PharmaVoice

Published July 8, 2025 Michael Gibney Senior Editor & Writer post share post print email license Getty Images via Getty Images Listen to the article 4 min This audio is auto-generated. Following years of relatively unsubstantial M&A in the biopharma industry, will 2025 be a long-awaited turning point?

Packaging 130